公开(公告)号：US09771320B2

公开(公告)日：2017-09-26

申请号：US15109741

申请日：2015-01-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jingwu Duan ,  T. G. Murali Dhar ,  Bin Jiang ,  Zhonghui Lu ,  Ananta Karmakar ,  Arun Kumar Gupta ,  Carolyn A. Weigelt

IPC: C07C317/14 ,  C07D213/81 ,  C07D401/04 ,  C07D237/08 ,  C07C317/20 ,  C07C317/30 ,  C07C317/46 ,  C07D471/04 ,  C07D213/30 ,  C07D213/56 ,  C07D309/04 ,  C07D309/14 ,  C07D317/44 ,  C07D231/12 ,  C07D239/38 ,  C07D241/12 ,  C07D471/10 ,  C07D257/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D211/36 ,  C07D295/16 ,  C07D295/20 ,  C07D303/06 ,  C07D305/14 ,  C07D205/04 ,  C07D211/62 ,  C07D213/40 ,  C07D213/75 ,  C07D295/155 ,  C07D295/108 ,  C07D319/20 ,  C07D285/06 ,  C07D295/18 ,  C07D295/22 ,  C07D303/34 ,  C07C317/22 ,  C07C317/44 ,  C07C317/32 ,  C07C317/50 ,  C07D213/85 ,  C07D295/185

CPC classification number: C07C317/14 ,  C07C317/20 ,  C07C317/22 ,  C07C317/30 ,  C07C317/32 ,  C07C317/44 ,  C07C317/46 ,  C07C317/50 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07D205/04 ,  C07D211/36 ,  C07D211/62 ,  C07D213/30 ,  C07D213/40 ,  C07D213/56 ,  C07D213/75 ,  C07D213/81 ,  C07D213/85 ,  C07D231/12 ,  C07D237/08 ,  C07D239/38 ,  C07D241/12 ,  C07D257/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D285/06 ,  C07D295/108 ,  C07D295/155 ,  C07D295/18 ,  C07D295/185 ,  C07D295/20 ,  C07D295/22 ,  C07D303/06 ,  C07D303/34 ,  C07D305/14 ,  C07D309/04 ,  C07D309/14 ,  C07D317/44 ,  C07D319/20 ,  C07D401/04 ,  C07D471/04 ,  C07D471/10

Abstract: Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.